F-box and leucine rich repeat protein 15Genealiases: FBXO37 · Fbl15 · JET
Q-omics provides the consensus-scored FBXL15 profile across patient tissues and cancer cell-line models. FBXL15 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FBXL15 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, FBXL15 protein abundance shows 30,785 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where FBXL15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL15 survival associations across molecular data types. FBXL15 RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL15 RNA expression–survival associations across cancer types. High FBXL15 expression shows unfavorable associations in ACC, UCS and COAD, but favorable associations in MESO, LGG and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FBXL15 RNA expression.
This table summarizes FBXL15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 10. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXL15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL15 shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in LIHC, CHOL and STAD. The LIHC box plot shows higher FBXL15 RNA expression in tumor versus normal tissue (log2 FC = +0.792, t-test p < 0.001).
This table shows molecular features associated with FBXL15 in patient tissues and cancer cell lines. In patient samples, FBXL15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
